July 15, 2024  – X-CUTAG and Medicilon officially inaugurated a joint laboratory on July 15, marking a strategic partnership aimed at enhancing drug discovery, molecular design, and preclinical research.

This collaboration leverages the combined expertise and resources of both companies to expedite the development and clinical application of innovative drugs. The newly established joint laboratory will provide precise services such as project evaluation and molecular design, supported by X-CUTAG's cutting-edge "deuterium +"  technology platform and Medicilon's extensive experience in developing over 600 marketed drugs. With more than 20 years of experience in the pharmaceutical industry, Medicilon will offer comprehensive R&D services to pharmaceutical companies, aiming to accelerate drug development and bring better drugs to market faster.

The joint laboratory is now fully operational and is expected to play a pivotal role in advancing the biomedical industry. Through collaborative innovation, the lab aims to foster high-quality development and contribute to the global effort to improve patient outcomes.

About X-CUTAG

X-CUTAG is a leading biotechnology company focused on the development of innovative drugs using advanced "deuterium +" technology. The company's mission is to enhance the safety, efficacy, and pharmacokinetic properties of new drugs, thereby improving patient care and treatment options.

About Medicilon

Medicilon is a renowned contract research organization (CRO) with over two decades of experience in providing comprehensive R&D services to the pharmaceutical industry. The company has a proven track record of successfully bringing over 600 drugs to market and is committed to accelerating the drug development process through its state-of-the-art facilities and expert team.